OF
INDV icon

Optimize Financial’s Indivior Pharmaceuticals INDV Stock Holding History

Optimize Financial’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$562K Sell
13,687
-47
-0.3% -$1.71K 0.2% 111
2026
Q1 		$419K Buy
+13,734
New +$454K 0.21% 182

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Optimize Financial's INDV Position: Q2 2026 in Review

Optimize Financial reduced its Indivior Pharmaceuticals (INDV) stake by 0.34% in Q2 2026, selling an estimated $1.71K and leaving 13,687 shares worth $562K. The position accounts for 0.2% of the portfolio, ranked #111.

Optimize Financial first reported a position in INDV in Q1 2026 and has held it in 2 quarters since. 339 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Optimize Financial held 13,687 shares of Indivior Pharmaceuticals worth $562K as of Q2 2026.
  • Optimize Financial sold 47 Indivior Pharmaceuticals shares in Q2 2026, an estimated $1.71K.
  • Indivior Pharmaceuticals made up 0.2% of Optimize Financial's portfolio in Q2 2026, its #111 holding.
  • Optimize Financial first reported a position in Indivior Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 339 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Optimize Financial's 13F filing for Q2 2026, filed 27 Aug 2026.